COGT vs SNY: How Cogent Biosciences and Sanofi Compare (2026)

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. COGT and SNY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined COGT and SNY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Cogent Biosciences is a Waltham, Massachusetts and Boulder, Colorado biotechnology company building precision therapies for genetically defined diseases. Its lead asset, bezuclastinib, is a tyrosine kinase inhibitor designed to hit the KIT D816V mutation and other KIT exon 17 mutations. That single molecule underpins three indications: non-advanced systemic mastocytosis (the SUMMIT trial), advanced systemic mastocytosis (APEX), and gastrointestinal stromal tumors after imatinib, where it is paired with sunitinib (the PEAK trial). Behind bezuclastinib sits an early research portfolio aimed at ErbB2, PI3K alpha, KRAS and JAK2, with CGT4255 and CGT6297 entering Phase 1 in 2026 and IND filings planned for CGT1815 and CGT1145.

Full COGT guide

Sanofi S.A. is one of the world's largest pharmaceutical companies, based in France and organized around biopharma (specialty care, general medicines) and vaccines. Its single most important product is Dupixent, an immunology drug co-developed with Regeneron that treats conditions like eczema, asthma, and COPD; Dupixent sales moved above the roughly four-billion-euro-per-quarter mark in Q1 2026 and grew more than 30% year over year, making it the engine of the company's revenue growth. Sanofi also runs a major vaccines business (including the RSV antibody Beyfortus and the newly acquired hepatitis-B vaccine Heplisav-B) and spun off its consumer-health arm, Opella (Allegra, Icy Hot, Dulcolax), in 2025 to focus purely on innovative medicines and vaccines.

Full SNY guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• COGT drivers: Three regulatory decisions inside twelve months; Systemic mastocytosis is the larger commercial prize.
• SNY drivers: Dupixent as the growth engine; Pipeline and new launches.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Everything routes through one molecule, so a complete response letter, a label restriction or a safety signal on any of the three applications hits the whole company at once. For SNY, the clearest risk is concentration in Dupixent: with one product carrying so much of the growth, its eventual loss of patent exclusivity later this decade is the central overhang, and the pipeline may or may not fully replace it.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick COGT if you believe its drivers more; SNY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the COGT and SNY guides.

COGT. There is no earnings multiple here because there are no earnings and no product sales, so the market is valuing probability-weighted future revenue from bezuclastinib across three indications. Net of roughly $866 million in cash and about $223 million of convertible notes, the enterprise value sits near $6.6 billion, which implies the market already assumes at least one approval and a credible launch. Quarterly cash burn ran near $87 million in the first quarter of 2026 and G&A more than doubled year over year on commercial build-out, so the burn rate rises before any revenue arrives.

SNY. Figures are approximate, drawn from public 2026 reporting, and tied to the asOf date; verify live numbers before acting. Sanofi reports in euros, so the dollar value of SNY and its dividend also depends on the euro-to-dollar exchange rate. As a defensive large-cap pharma, the stock tends to trade on pipeline news, Dupixent momentum, and the eventual patent-expiry timeline rather than on sharp cyclical swings.

Headline figures (approximate, August 2026): COGT shows market cap ~$7.2B, revenue (ttm) ~$0 (no approved product), net loss (ttm) ~$354M, cash and marketable securities (mar 31, 2026) ~$866M; SNY shows company type Large-cap, diversified global pharmaceutical company (French, US-listed as an ADR on Nasdaq), market cap ~$107 billion (approximate; among the larger global pharma names), q1 2026 revenue ~10.5 billion euros, ahead of consensus (reported figures are in euros), q1 2026 business eps ~1.88 euros, up ~14% at constant exchange rates.

COGT and SNY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined COGT and SNY exposure against your real portfolio. It is not an investment adviser.